JP2021506747A - 修飾CκおよびCH1ドメイン - Google Patents
修飾CκおよびCH1ドメイン Download PDFInfo
- Publication number
- JP2021506747A JP2021506747A JP2020524871A JP2020524871A JP2021506747A JP 2021506747 A JP2021506747 A JP 2021506747A JP 2020524871 A JP2020524871 A JP 2020524871A JP 2020524871 A JP2020524871 A JP 2020524871A JP 2021506747 A JP2021506747 A JP 2021506747A
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- human
- antibody
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
「1つの(「a」または「an」)」のエンティティという用語は、そのエンティティの1または複数を指すことに留意されたい。例えば「1つの(「an」)抗体」は、1または複数の抗体を表すと理解される。したがって、1つ(「a」(または「an」))、「1または複数」および「少なくとも1つ」という用語は、本明細書では互換的に使用され得る。
CH1のIMGTエクソン番号付けおよびKabat番号付け
[表1]26位および任意に11位におけるCκの変異基、11位および任意に28位におけるCH1の変異基
[表2]Cκ17/CH1 9の変異基
[表3]破壊され再建された塩橋
水素結合(カットオフ距離:3.5Å)
1F8のCκとCH1との間の塩橋
1F8 CH1の界面残基:
1F8 Cκの界面残基:
水素結合(カットオフ距離:3.5Å)
界面残基:1cz8 CH1
界面残基:1cz8 Cκ
1L7iの疎水性界面
界面残基:1L7i CH1
界面残基:1L7i Cκ
構造4:4NYLのCκおよびCH1の界面相互作用の解析
4NYLの水素結合(カットオフ距離:3.5Å)
4NYLのCKとCHとの間の塩橋
4NYLの疎水性界面
界面残基:4NYL CH1
界面残基:4NYL Cκ
CH1の配列再コード化
[表4]Cκ/CH1相互作用に影響を与える残基対
アラニンのスクリーニング
CH1:LYS96>ASP変異およびCk:GLU16>ARG変異
CH1:LYS96>GLU変異およびCk:GLU16>ARG変異
[表5]CH1_K96/Cκ_E16の変異
[表7]変異を含む試験抗体
[表8]変異を有する試験抗体
[表9]変異を有する試験抗体
Claims (23)
- L11W置換体を含むヒトCH1断片と、V26W置換体を含むヒトCκ断片とを備える、抗体またはその抗原結合断片。
- 前記ヒトCH1断片が置換体L11WおよびK101Eを含み、前記ヒトCκ断片が置換体V26WおよびD15K/Hを含む、請求項1に記載の抗体またはその抗原結合断片。
- 前記ヒトCH1断片が置換体L11WおよびK96Dを含み、前記ヒトCκ断片が置換体V26WおよびE16Rを含む、請求項1に記載の抗体またはその抗原結合断片。
- 前記ヒトCH1断片が置換体L11WおよびK96Eを含み、前記ヒトCκ断片が置換体V26WおよびE16Kを含む、請求項1に記載の抗体またはその抗原結合断片。
- 前記ヒトCH1断片が置換体L11WおよびK96Eを含み、前記ヒトCκ断片が置換体V26WおよびE16Rを含む、請求項1に記載の抗体またはその抗原結合断片。
- 置換体L11Wを含まない第2のヒトCH1断片と、
置換体V26Wを含まない第2のヒトCκ断片と
をさらに備える、請求項1に記載の抗体またはその抗原結合断片。 - 前記第2のヒトCH1断片および前記第2のヒトCκ断片が野生型である、請求項6に記載の抗体またはその抗原結合断片。
- 重鎖可変領域、軽鎖可変領域、Fc領域、またはそれらの組み合わせをさらに備える、請求項1から7のいずれか一項に記載の抗体またはその抗原結合断片。
- クラスIgGである、請求項8に記載の抗体またはその抗原結合断片。
- アイソタイプがIgG1、IgG2、IgG3またはIgG4である、請求項9に記載の抗体またはその抗原結合断片。
- ヒトCH1断片とヒトCκ断片との対を備え、前記ヒトCH1断片および前記ヒトCκ断片は、
(a)CH1のL11KおよびL28N、CκのV26W;
(b)CH1のL11W、およびCκのF11WおよびV26G;
(c)CH1のF9D、CκのQ17RまたはQ17K;ならびに
それらの組み合わせ
からなる群から選択される置換体を含む、抗体またはその抗原結合断片。 - 前記ヒトCH1断片および前記ヒトCκ断片がさらに、(a)CH1のK101EおよびCκのD15K/H、(b)CH1のK96DおよびCκのE16R、(c)CH1のK96EおよびCκのE16K、ならびに(d)CH1のK96EおよびCκのE16Rからなる群から選択される置換体を含む、請求項10に記載の抗体またはその抗原結合断片。
- Leu11位にアミノ酸置換体を含むヒトCH1断片と、V26位および/またはF11位にアミノ酸置換体を含むヒトCκ断片とを備え、前記ヒトCH1断片が前記ヒトCκ断片と対合すると、前記アミノ酸置換体が相互作用する、抗体またはその抗原結合断片。
- 前記ヒトCH1断片が野生型ヒトCκドメインと相互作用せず、ヒトCκドメインが野生型ヒトCH1断片と相互作用しない、請求項13に記載の抗体またはその抗原結合断片。
- 前記アミノ酸置換体が表1から選択される、請求項13に記載の抗体またはその抗原結合断片。
- F9位にアミノ酸置換体を含むヒトCH1断片と、Q17位にアミノ酸置換体を含むヒトCκ断片とを備え、前記ヒトCH1断片が前記ヒトCκ断片と対合すると、前記アミノ酸置換体が相互作用する、抗体またはその抗原結合断片。
- 前記ヒトCH1断片が野生型ヒトCκ断片と相互作用せず、前記ヒトCκ断片が野生型ヒトCH1断片と相互作用しない、請求項16に記載の抗体またはその抗原結合断片。
- 前記アミノ酸置換体が表2から選択される、請求項16に記載の抗体またはその抗原結合断片。
- 重鎖可変領域、軽鎖可変領域、Fc領域、またはそれらの組み合わせをさらに備える、請求項10から18のいずれか一項に記載の抗体またはその抗原結合断片。
- 第1のCH1/Cκ対と第2のCH1/Cκ対とを備える二重特異性抗体であって、前記第1のCH1/Cκ対のCH1断片およびCκ断片は、CH1のL11WおよびCκのV26Wのアミノ酸置換体を含み、前記第2のCH1/Cκ対のCH1断片およびCκ断片は、L11WおよびV26W置換体を含まない、二重特異性抗体。
- 前記第1のCH1/Cκ対のCH1断片およびCκ断片が、(a)CH1のK101EおよびCκのD15K/H、(b)CH1のK96DおよびCκのE16R、ならびに(c)CH1のK96EおよびCκのE16Kからなる群から選択される置換体をさらに含み、前記第2のCH1/Cκ対のCH1断片およびCκ断片は、(a)から(c)の前記置換体を含まない、請求項20に記載の二重特異性抗体。
- 請求項1から19のいずれか一項に記載の抗体またはその抗原結合断片、および医薬上許容し得る担体を備える、組成物。
- 請求項1から19のいずれか一項に記載の抗体またはその抗原結合断片をコードする1または複数のポリヌクレオチドを備える、単離された細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/072564 | 2018-01-15 | ||
CN2018072564 | 2018-01-15 | ||
PCT/CN2019/071740 WO2019137552A1 (en) | 2018-01-15 | 2019-01-15 | MODIFIED Cκ AND CH1 DOMAINS |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021506747A true JP2021506747A (ja) | 2021-02-22 |
JP6996825B2 JP6996825B2 (ja) | 2022-01-17 |
Family
ID=67219407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524871A Active JP6996825B2 (ja) | 2018-01-15 | 2019-01-15 | 修飾CκおよびCH1ドメイン |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190389972A1 (ja) |
EP (1) | EP3577141A4 (ja) |
JP (1) | JP6996825B2 (ja) |
KR (1) | KR102471868B1 (ja) |
CN (1) | CN110573531B (ja) |
AU (2) | AU2019203917B2 (ja) |
BR (1) | BR112020009414A2 (ja) |
CA (1) | CA3084398A1 (ja) |
EA (1) | EA202091053A1 (ja) |
IL (1) | IL275943B (ja) |
MX (1) | MX2020006942A (ja) |
SG (1) | SG11202005009RA (ja) |
WO (1) | WO2019137552A1 (ja) |
ZA (1) | ZA202002567B (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009541275A (ja) * | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
JP2014522644A (ja) * | 2011-07-07 | 2014-09-08 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | 多重特異性抗体 |
WO2017055537A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Tetravalent multispecific antibodies |
JP2017521361A (ja) * | 2014-05-16 | 2017-08-03 | ファイザー・インク | 二重特異性抗体 |
WO2017162890A1 (en) * | 2016-03-25 | 2017-09-28 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
CA2890575C (en) * | 2012-11-05 | 2021-11-09 | Jumpei Enami | Antibody and antibody composition production method |
WO2014150973A1 (en) * | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
AU2015265457B2 (en) * | 2014-05-28 | 2021-02-18 | Zymeworks Bc Inc. | Modified antigen binding polypeptide constructs and uses thereof |
SG11201703597TA (en) * | 2014-11-14 | 2017-06-29 | Hoffmann La Roche | Antigen binding molecules comprising a tnf family ligand trimer |
JP7239320B2 (ja) * | 2015-10-02 | 2023-03-14 | エフ. ホフマン-ラ ロシュ アーゲー | 多重特異性抗体 |
WO2017097723A2 (en) * | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Treatment method |
WO2017117179A1 (en) * | 2015-12-28 | 2017-07-06 | Massachusetts Institute Of Technology | Bispecific antibodies having constant region mutations and uses therefor |
-
2019
- 2019-01-15 EA EA202091053A patent/EA202091053A1/ru unknown
- 2019-01-15 US US16/489,970 patent/US20190389972A1/en active Pending
- 2019-01-15 AU AU2019203917A patent/AU2019203917B2/en active Active
- 2019-01-15 BR BR112020009414-5A patent/BR112020009414A2/pt unknown
- 2019-01-15 MX MX2020006942A patent/MX2020006942A/es unknown
- 2019-01-15 EP EP19730101.3A patent/EP3577141A4/en active Pending
- 2019-01-15 SG SG11202005009RA patent/SG11202005009RA/en unknown
- 2019-01-15 JP JP2020524871A patent/JP6996825B2/ja active Active
- 2019-01-15 WO PCT/CN2019/071740 patent/WO2019137552A1/en unknown
- 2019-01-15 CN CN201980001527.7A patent/CN110573531B/zh active Active
- 2019-01-15 KR KR1020197022000A patent/KR102471868B1/ko active IP Right Grant
- 2019-01-15 CA CA3084398A patent/CA3084398A1/en active Pending
-
2020
- 2020-05-08 ZA ZA2020/02567A patent/ZA202002567B/en unknown
- 2020-05-08 AU AU2020203065A patent/AU2020203065B2/en not_active Expired - Fee Related
- 2020-07-09 IL IL275943A patent/IL275943B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009541275A (ja) * | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
JP2014522644A (ja) * | 2011-07-07 | 2014-09-08 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | 多重特異性抗体 |
JP2017521361A (ja) * | 2014-05-16 | 2017-08-03 | ファイザー・インク | 二重特異性抗体 |
WO2017055537A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Tetravalent multispecific antibodies |
WO2017162890A1 (en) * | 2016-03-25 | 2017-09-28 | Biomunex Pharmaceuticals | Binding molecules to cd38 and pd-l1 |
Non-Patent Citations (1)
Title |
---|
MOLECULAR IMMUNOLOGY, vol. 23, no. 9, JPN6020051307, 1986, pages 951 - 960, ISSN: 0004421793 * |
Also Published As
Publication number | Publication date |
---|---|
IL275943A (en) | 2020-08-31 |
WO2019137552A1 (en) | 2019-07-18 |
AU2019203917A1 (en) | 2019-08-01 |
BR112020009414A2 (pt) | 2020-11-03 |
SG11202005009RA (en) | 2020-06-29 |
EP3577141A1 (en) | 2019-12-11 |
EP3577141A4 (en) | 2021-02-17 |
KR20200059186A (ko) | 2020-05-28 |
JP6996825B2 (ja) | 2022-01-17 |
KR102471868B1 (ko) | 2022-11-30 |
US20190389972A1 (en) | 2019-12-26 |
AU2020203065B2 (en) | 2023-04-06 |
MX2020006942A (es) | 2020-09-14 |
AU2020203065A1 (en) | 2020-05-28 |
AU2019203917B2 (en) | 2020-04-02 |
CN110573531B (zh) | 2021-04-02 |
EA202091053A1 (ru) | 2020-12-03 |
IL275943B (en) | 2022-06-01 |
ZA202002567B (en) | 2021-04-28 |
CN110573531A (zh) | 2019-12-13 |
CA3084398A1 (en) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102939305B (zh) | 对cd122的抗体 | |
CN110945026B (zh) | 仅有重链的抗bcma抗体 | |
JP2019527061A (ja) | 抗gprc5d抗体、gprc5dとcd3を結合する二重特異性抗原結合分子、及びその使用 | |
JP2021524249A (ja) | 抗cd3抗体及びその使用 | |
CN111744013B (zh) | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 | |
CA2954476C (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
TW202406935A (zh) | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 | |
JP2020524506A (ja) | 抗bcma重鎖のみ抗体 | |
JP2021526022A (ja) | 抗インターロイキン17a抗体、医薬組成物、およびその使用 | |
TW201116625A (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
JP2023106392A (ja) | Cd3抗原結合性断片及びその使用 | |
JP2002530066A (ja) | Rhammアンタゴニスト抗体 | |
KR20210096559A (ko) | 항IL-23p19 항체 및 이의 용도 | |
CN114269380A (zh) | IgM糖变体 | |
CN113164780A (zh) | 抗lap抗体变体及其用途 | |
KR20180030917A (ko) | 항-cd154 항체 및 그의 사용 방법 | |
TR201810773T4 (tr) | Onkostatin m?ye (osm) antijen bağlayıcı proteinler. | |
EP3317299A1 (en) | Multi-specific binding proteins | |
JP6996825B2 (ja) | 修飾CκおよびCH1ドメイン | |
JP2024505674A (ja) | 抗il1rap抗体 | |
GB2576914A (en) | Antigen-binding molecules comprising unpaired variable domains produced in mammals | |
CN115521378B (zh) | Pd-l1抗体及其用途 | |
JP2013177317A (ja) | 抗pdgf受容体抗体 | |
CN117157314A (zh) | Pd-l1抗体、融合蛋白及其用途 | |
CN116847863A (zh) | 抗人cd22的单克隆抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200820 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200707 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200820 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20201215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210922 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6996825 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |